Anixa Biosciences ANIX 深 沪
等待开盘 10-15 09:30:00 美东时间
2.69
+0.020
+0.75%
华盛通- 最 高2.818
- 今 开2.64
- 成交量 14.44万股
- 最 低 2.63
- 昨 收 2.67
- 总市值 9351.46万
- 52周最高 5.4566
- 市盈率 静 --
- 换手率 0.42%
- 52周最低 2.32
- 委 比 92.43%
- 总股本 3476.38万
- 历史最高 8.09
- 量 比 0.95
- 振 幅 7.04%
- 历史最低 1.33
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Anixa Biosciences Announces Second Patient Has Been Treated In Fifth Cohort Of Its Ongoing Phase 1, Dose-Escalating, Clinical Trial Evaluating FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer
The study is being conducted at Moffitt Cancer Center ("Moffitt"). The Phase 1 study is evaluating a novel CAR-T therapy targeting follicle stimulating hormone receptor (FSHR), which is expressed on ovarian cancer cells but has limited expression in healthy tissues. The trial is designed to assess ...
10-01 20:40
美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
IP Australia Grants Patent To Anixa Biosciences’ Breast Cancer Vaccine Technology, Exclusively Licensed From Cleveland Clinic
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estate Continues expansion of global intellectual property coverage in markets with increasing breast cancer incidence rates SAN JOSE, Cali...
09-21 20:47
Anixa Biosciences Q3 EPS $(0.08) Beats $(0.09) Estimate, Sales $0.00, Same YoY
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 14.29 percent decrease over losses of $(0.07) per share from the same period last year. The company reported $0.00 in sales this quarter. Th...
09-10 05:14
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 mo...
08-18 20:45
Anixa Biosciences乳腺癌疫苗技术获澳大利亚专利批准
Anixa Biosciences（股票代码：ANIX）今日宣布，其开发的乳腺癌疫苗技术已获得澳大利亚专利局的专利批准。这一进展标志着该公司在全球知识产权布...
07-14 23:51
Anixa Biosciences Issued Notice Of Acceptance From IP Australia For Its Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued a Notice of Acceptance for a new patent related to Anixa's breast cancer vaccine technology.
07-14 20:35
Anixa Biosciences Doses First Participant In Fifth Group Of Its Phase 1 Clinical Study Of CAR-T/CER-T Therapy For Recurrent Ovarian Cancer
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the first patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT053...
07-06 20:36
Anixa Biosciences Announces Its Breast Cancer Vaccine's Final Phase 1 Data Shows All Major Primary Endpoints Met, Protocol-Defined Immune Responses Generated In 74% Of Participants
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its two clinical-stage immunotherapy programs were presented at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy sympos...
06-26 21:13
